DataMeds AI Inks LOI for Transformative Reverse Merger with EOS, Scilex, Datavault, and HBA
MEDS sits 28% above its 52-week low of $2.485.
Summary
DataMeds AI signed a non-binding LOI for a reverse merger that would give EOS, Scilex, Datavault, and HBA ~84.6% ownership, leaving public shareholders with ~10.4%. The deal includes IP acquisitions, license expansion, and a controlling stake in Tollo Health, alongside immediate management changes and a $2M minimum investment.
Key Events · M&A and Partnerships · MEDS
-
Transformative LOI Signed
On July 29, 2026, DataMeds AI entered an Amended and Restated LOI to acquire QLPM IP from EOS and Scilex, expand its Datavault license, and acquire a controlling interest in Tollo Health from HBA, in exchange for common stock.
-
Post-Close Ownership Shift
Upon closing, EOS, Scilex, Datavault, and HBA would collectively own ~84.6% of MEDS common stock, with existing public shareholders diluted to ~10.4% on a fully diluted basis, subject to adjustments.
-
Immediate Leadership Changes
To facilitate the transaction, Gerald Commissiong of Fortitude Advisors has been appointed Interim Co-CEO alongside current President Prashant Patel, and Dan Hirsch has been hired as Interim VP of Finance.
-
Minimum $2M Investment and ATM
The LOI requires a concurrent minimum $2 million investment from Dawson James Investors and an At-The-Market facility filing within 14 days to address outstanding liabilities.
Analysis · MEDS · Trade & Services
DataMeds AI has entered into an Amended and Restated Letter of Intent that would fundamentally reshape the company. The proposed transaction brings in QLPM drone-delivery IP, expands a blockchain healthcare license, and acquires Tollo Health—with the selling parties taking roughly 84.6% ownership post-close. Existing public shareholders would be diluted to approximately 10.4%. The LOI also triggers immediate leadership changes, a $2 million minimum investment, and an ATM filing. While still non-binding and subject to due diligence, financing, and shareholder approval, the proposed terms represent a near-total change of control and a pivot to a new business focus. The exclusivity period runs through September 30, 2026, locking the company into negotiations. If consummated, this would be a thesis-altering event for current MEDS holders.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 42.7% of the 288 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MEDS was trading at $3.17 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $8.3M. The 52-week trading range was $2.48 to $97.50. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.